Literature DB >> 12680591

Properties of chimeric prostacyclin/prostaglandin D2 receptors: site-directed mutagenesis reveals the significance of the isoleucine residue at position 323.

Helen Wise1, Kevin B S Chow, Kam Yiu Wing, Takuya Kobayashi, Dicky L Y Tse, Christopher H K Cheng.   

Abstract

Mouse prostacyclin (mIP) receptors transiently expressed in Chinese hamster ovary (CHO) cells activated both adenylyl cyclase and phospholipase C, with a 33-fold preference for signaling through Gs. The prostacyclin (IP) receptor agonists cicaprost, iloprost, carbacyclin, and prostaglandin E1 showed a similar order of potency for activation of both signaling pathways in cells transiently transfected with the mIP and the chimeric prostacyclin/prostaglandin D2 (IPN-VII/DPC and IPN-V/DPVI-C) receptors. Substitution of the carboxyl-terminal tail of the prostacyclin receptor with the corresponding region of the mDP receptor (IPN-VII/DPC) produced a receptor with increased coupling to both Gs and Gq. However, this increased G-protein coupling was lost in the IPN-V/DPVI-C receptor. The observation that both these chimeric receptors can activate phospholipase C indicates that the carboxyl-terminal tail of the IP receptor is not entirely responsible for its ability to couple to Gq. Site-directed mutagenesis studies suggest that isoleucine at position 323 in the IPN-VII/DPC receptor plays an important role in mediating the increased potency of this chimeric receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680591     DOI: 10.1081/rrs-120018762

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  1 in total

1.  Mapping the Molecular Architecture Required for Lipid-Binding Pockets Using a Subset of Established and Orphan G-Protein Coupled Receptors.

Authors:  Shanthi Nagarajan; Zu Yuan Qian; Parthiban Marimuthu; Nabil J Alkayed; Sanjiv Kaul; Anthony P Barnes
Journal:  J Chem Inf Model       Date:  2021-07-09       Impact factor: 6.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.